Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake challenges.

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

American pharmaceutical company Moderna (MRNA) is reportedly under scrutiny by U.S. President Donald Trump’s team, which is ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

Moderna’s Q4 2024 earnings call highlighted its ongoing challenges in the respiratory vaccine market and its ... while cost reductions and a cash cost target of $5.5 billion in 2025 demonstrate ...

Such research was underway well before the coronavirus pandemic thrust mRNA vaccination into the spotlight, said Kamath, who is working with the company Moderna ... vaccine for that particular ...

"Our RSV vaccine will be manufactured at the Moderna Innovation and Technology ... The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is ...